Found: 11
Select item for more details and to access through your institution.
Phase I Trial of Everolimus and Capecitabine in Metastatic HER2<sup>-</sup> Breast Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
- Published in:
- Breast Cancer Research, 2014, v. 16, n. 3, p. 1, doi. 10.1186/bcr3661
- By:
- Publication type:
- Article
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 2, p. 399, doi. 10.1007/s00280-014-2500-2
- By:
- Publication type:
- Article
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 5, p. 642, doi. 10.1002/cncr.28465
- By:
- Publication type:
- Article
Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting.
- Published in:
- Oncologist, 2014, v. 19, n. 9, p. 901, doi. 10.1634/theoncologist.2014-0059
- By:
- Publication type:
- Article
Author's Response to "A Letter in Support of Real-World RECIST".
- Published in:
- 2020
- By:
- Publication type:
- Letter
Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach.
- Published in:
- Genome Medicine, 2019, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13073-019-0652-8
- By:
- Publication type:
- Article